{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:52:17Z","timestamp":1781592737072,"version":"3.54.5"},"reference-count":34,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,5,1]]},"DOI":"10.3724\/abbs.2025249","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T06:03:24Z","timestamp":1766383404000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Targeting lactate with a GLUT1 inhibitor reverses PARP                     inhibitor resistance in ovarian cancer"],"prefix":"10.3724","author":[{"given":"Shuqi","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congli","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"Ledermann JA","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO                         clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013, 24: vi24-vi32.","journal-title":"Ann Oncol"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/AOG.0000000000000981","volume":"126","author":"Cress RD","year":"2015","unstructured":"Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of long-term survivors of epithelial ovarian                         cancer. Obstet                             Gynecol, 2015, 126: 491-497.","journal-title":"Obstet                             Gynecol"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"Banerjee S","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M. Maintenance olaparib for patients with newly diagnosed advanced                         ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a                         randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2021, 22: 1721-1731.","journal-title":"Lancet Oncol"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"DiSilvestro P","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M. Overall survival with maintenance olaparib at a 7-year follow-up                         in patients with newly diagnosed advanced ovarian cancer and a BRCA                         mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol, 2023, 41: 609-617.","journal-title":"J Clin Oncol"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"Pujade-Lauraine E","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J. Olaparib tablets as maintenance therapy in patients with                         platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation                         (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3                         trial. Lancet Oncol, 2017, 18: 1274-1284.","journal-title":"Lancet Oncol"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"Poveda A","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J. Olaparib tablets as maintenance therapy in patients with                         platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation                         (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised,                         placebo-controlled, phase 3 trial. Lancet Oncol, 2021, 22: 620-631.","journal-title":"Lancet Oncol"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"112908","DOI":"10.1016\/j.ejca.2023.04.024","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn A","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G. Progression-free survival and safety at 3.5 years of follow-up:                         results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of                         niraparib maintenance treatment in patients with newly diagnosed ovarian                         cancer. Eur J Cancer, 2023, 189:","journal-title":"Eur J Cancer"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"Monk BJ","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC. Niraparib first-line maintenance therapy in patients with newly                         diagnosed advanced ovarian cancer: final overall survival results from the                         PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol, 2024, 35: 981-992.","journal-title":"Ann Oncol"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","volume":"32","author":"Wu XH","year":"2021","unstructured":"Wu XH, Zhu JQ, Yin RT, Yang JX, Liu JH, Wang J, Wu LY. Niraparib maintenance therapy in patients with platinum-sensitive                         recurrent ovarian cancer using an individualized starting dose (NORA): a                         randomized, double-blind, placebo-controlled phase III trial. Ann Oncol, 2021, 32: 512-521.","journal-title":"Ann Oncol"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","volume":"33","author":"Frenel JS","year":"2022","unstructured":"Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, Pautier P. Efficacy of subsequent chemotherapy for patients with                         BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib                         versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial. Ann Oncol, 2022, 33: 1021-1028.","journal-title":"Ann Oncol"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ygyno.2022.02.002","volume":"165","author":"Park J","year":"2022","unstructured":"Park J, Kim SI, Jeong SY, Kim Y, Bookman MA, Kim JW, Kim BG. Second-line olaparib maintenance therapy is associated with poor                         response to subsequent chemotherapy in BRCA1\/2-mutated epithelial ovarian                         cancer: a multicentre retrospective study. Gynecol Oncol, 2022, 165: 97-104.","journal-title":"Gynecol Oncol"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s41416-023-02555-w","volume":"130","author":"Wang Y","year":"2024","unstructured":"Wang Y, He M, He T, Ouyang X, Shen X, Shi W, Huang S. Integrated genomic and transcriptomic analysis reveals the                         activation of PI3K signaling pathway in HPV-independent cervical cancers. Br J Cancer, 2024, 130: 987-1000.","journal-title":"Br J Cancer"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"216064","DOI":"10.1016\/j.canlet.2023.216064","volume":"556","author":"Jiang W","year":"2023","unstructured":"Jiang W, Ouyang X, Ji Z, Shi W, Wu Y, Yao Q, Wang Y. The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by                         promoting glutamine metabolism in cervical cancer. Cancer Lett, 2023, 556:","journal-title":"Cancer Lett"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"Kopper O","year":"2019","unstructured":"Kopper O, de Witte CJ, L\u00f5hmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV. An organoid platform for ovarian cancer captures intra- and                         interpatient heterogeneity. Nat Med, 2019, 25: 838-849.","journal-title":"Nat Med"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.cmet.2024.07.011","volume":"36","author":"Li G","year":"2024","unstructured":"Li G, Wang D, Zhai Y, Pan C, Zhang J, Wang C, Huang R. Glycometabolic reprogramming-induced XRCC1 lactylation confers                         therapeutic resistance in ALDH1A3-overexpressing glioblastoma. Cell Metab, 2024, 36: 1696-1710.e10.","journal-title":"Cell Metab"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","volume":"631","author":"Chen H","year":"2024","unstructured":"Chen H, Li Y, Li H, Chen X, Fu H, Mao D, Chen W. NBS1 lactylation is required for efficient DNA repair and                         chemotherapy resistance. Nature, 2024, 631: 663-669.","journal-title":"Nature"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.drup.2021.100744","volume":"55","author":"Chiappa M","year":"2021","unstructured":"Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G. Overcoming PARPi resistance: preclinical and clinical evidence in                         ovarian cancer. Drug Resist                             Updat, 2021, 55:","journal-title":"Drug Resist                             Updat"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"Wethington SL","year":"2023","unstructured":"Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA. CAPARI nhibitor (CAPRI) trial in acquired PARP                         inhibitor\u2013resistant homologous recombination\u2013deficient ovarian cancer. Clin Cancer                             Res, 2023, 29: 2800-2807.","journal-title":"Clin Cancer                             Res"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","volume":"131","author":"Smith HL","year":"2024","unstructured":"Smith HL, Willmore E, Prendergast L, Curtin NJ. ATR, CHK1 and WEE1 inhibitors cause homologous recombination                         repair deficiency to induce synthetic lethality with PARP inhibitors. Br J Cancer, 2024, 131: 905-917.","journal-title":"Br J Cancer"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"216820","DOI":"10.1016\/j.canlet.2024.216820","volume":"589","author":"Orhan E","year":"2024","unstructured":"Orhan E, Velazquez C, Tabet I, Fenou L, Rodier G, Orsetti B, Jacot W. CDK inhibition results in pharmacologic BRCAness increasing                         sensitivity to olaparib in BRCA1-WT and olaparib resistant in triple                         negative breast cancer. Cancer Lett, 2024, 589:","journal-title":"Cancer Lett"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41419-024-06913-1","volume":"15","author":"Di S","year":"2024","unstructured":"Di S, Chen W, Yang W, Zhang X, Dong K, Tian Y, Sun Y. DEPDC1 as a metabolic target regulates glycolysis in renal cell                         carcinoma through AKT\/mTOR\/HIF1\u03b1 pathway. Cell Death Dis, 2024, 15:","journal-title":"Cell Death Dis"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"2401399","DOI":"10.1002\/advs.202401399","volume":"11","author":"Lu Y","year":"2024","unstructured":"Lu Y, Zhu J, Zhang Y, Li W, Xiong Y, Fan Y, Wu Y. Lactylation-Driven IGF2BP3-Mediated serine metabolism                         reprogramming and RNA m6A\u2014modification promotes lenvatinib resistance in HCC. Adv Sci, 2024, 11:","journal-title":"Adv Sci"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-024-01928-8","volume":"9","author":"Zhang T","year":"2024","unstructured":"Zhang T, Pan Z, Gao J, Wu Q, Bai G, Li Y, Tong L. Branched-chain amino acid transaminase 1 confers EGFR-TKI                         resistance through epigenetic glycolytic activation. Sig Transduct                             Target Ther, 2024, 9:","journal-title":"Sig Transduct                             Target Ther"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s12276-024-01221-2","volume":"56","author":"Park W","year":"2024","unstructured":"Park W, Wei S, Xie CL, Han JH, Kim BS, Kim B, Jin JS. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S                         mutation-driven osimertinib resistance in non-small cell lung cancer. Exp Mol Med, 2024, 56: 1137-1149.","journal-title":"Exp Mol Med"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41388-021-02148-y","volume":"41","author":"Lin J","year":"2022","unstructured":"Lin J, Xia L, Oyang L, Liang J, Tan S, Wu N, Yi P. The POU2F1-ALDOA axis promotes the proliferation and                         chemoresistance of colon cancer cells by enhancing glycolysis and the                         pentose phosphate pathway activity. Oncogene, 2022, 41: 1024-1039.","journal-title":"Oncogene"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"102156","DOI":"10.1016\/j.tranon.2024.102156","volume":"50","author":"Qin R","year":"2024","unstructured":"Qin R, Fan X, Huang Y, Chen S, Ding R, Yao Y, Wu R. Role of glucose metabolic reprogramming in colorectal cancer                         progression and drug resistance. Transl Oncol, 2024, 50:","journal-title":"Transl Oncol"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"2402600","DOI":"10.1002\/advs.202402600","volume":"11","author":"Yang C","year":"2024","unstructured":"Yang C, Li Z, Tian K, Meng X, Wang X, Song D, Wang X. LncRNA-Mediated TPI1 and PKM2 promote self-renewal and                         chemoresistance in GBM. Adv Sci, 2024, 11:","journal-title":"Adv Sci"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12943-024-01939-7","volume":"23","author":"Bian Z","year":"2024","unstructured":"Bian Z, Yang F, Xu P, Gao G, Yang C, Cao Y, Yao S. LINC01852 inhibits the tumorigenesis and chemoresistance in                         colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM. Mol Cancer, 2024, 23:","journal-title":"Mol Cancer"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"101162","DOI":"10.1016\/j.xcrm.2023.101162","volume":"4","author":"Li Y","year":"2023","unstructured":"Li Y, Tang S, Shi X, Lv J, Wu X, Zhang Y, Wang H. Metabolic classification suggests the GLUT1\/ALDOB\/G6PD axis as a                         therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep Med, 2023, 4:","journal-title":"Cell Rep Med"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","volume":"35","author":"Wu L","year":"2023","unstructured":"Wu L, Jin Y, Zhao X, Tang K, Zhao Y, Tong L, Yu X. Tumor aerobic glycolysis confers immune evasion through                         modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1. Cell Metab, 2023, 35: 1580-1596.e9.","journal-title":"Cell Metab"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","volume":"574","author":"Zhang D","year":"2019","unstructured":"Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, Liu W. Metabolic regulation of gene expression by histone lactylation. Nature, 2019, 574: 575-580.","journal-title":"Nature"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1097\/HEP.0000000000000279","volume":"78","author":"Gao R","year":"2023","unstructured":"Gao R, Li Y, Xu Z, Zhang F, Xu J, Hu Y, Yin J. Mitochondrial pyruvate carrier 1 regulates fatty acid synthase                         lactylation and mediates treatment of nonalcoholic fatty liver disease. Hepatology, 2023, 78: 1800-1815.","journal-title":"Hepatology"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41592-022-01523-1","volume":"19","author":"Wan N","year":"2022","unstructured":"Wan N, Wang N, Yu S, Zhang H, Tang S, Wang D, Lu W. Cyclic immonium ion of lactyllysine reveals widespread                         lactylation in the human proteome. Nat Methods, 2022, 19: 854-864.","journal-title":"Nat Methods"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.cell.2023.11.022","volume":"187","author":"Chen Y","year":"2024","unstructured":"Chen Y, Wu J, Zhai L, Zhang T, Yin H, Gao H, Zhao F. Metabolic regulation of homologous recombination repair by MRE11                         lactylation. Cell, 2024, 187: 294-311.e21.","journal-title":"Cell"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/2E0ACCEE3E3B4FADA32A9ACBDE765014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025249","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/2E0ACCEE3E3B4FADA32A9ACBDE765014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:58:53Z","timestamp":1781589533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":34,"URL":"https:\/\/doi.org\/10.3724\/abbs.2025249","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}